Stockscreener 앱 받기
0.9023
6.45%
-0.0622
시간 외 거래:
.92
0.0177
+1.96%
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
Atyr Pharma: Fourth Quarter Earnings Overview - Bitget
aTyr Pharma (NASDAQ:ATYR) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
aTyr (ATYR) Achieves Milestone with Phase 3 Study Results - GuruFocus
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update - The Manila Times
Atyr Pharma: Q4 Earnings Snapshot - marketscreener.com
ATYR Financials: Income Statement, Balance Sheet & Cash Flow | Atyr Pharma Inc - Stock Titan
ATYR PE Ratio & Valuation, Is ATYR Overvalued - Intellectia AI
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
aTyr Pharma Faces Pivotal Regulatory and Financial Milestones - AD HOC NEWS
aTyr Pharma (ATYR) Stock Analysis: Exploring a Potential 327% Upside in the Biotech Sector - DirectorsTalk Interviews
aTyr Pharma Q4 2025 Earnings Call Transcript - MarketBeat
aTyr Pharma (NASDAQ:ATYR) Trading Down 2.1%Should You Sell? - MarketBeat
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
aTyr Pharma, Inc. (ATYR) Stock Analysis: Unveiling a Potential 338% Upside in the Biotechnology Arena - DirectorsTalk Interviews
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference - Bitget
aTyr Pharma Insiders Added US$926.8k Of Stock To Their Holdings - simplywall.st
ATyr Pharma to Present at the Leerink Partners Global Healthcare Conference - marketscreener.com
Sentiment Recap: Does aTyr Pharma Inc stock benefit from AI growth2025 Volatility Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Levels Update: Will CompoSecure Inc Equity Warrant stock go up in YEARVolume Spike & Low Volatility Stock Recommendations - baoquankhu1.vn
The Truth About aTyr Pharma Inc (LIFE): Tiny Stock, Huge Bets – But Is It Worth the Hype? - AD HOC NEWS
Is aTyr Pharma Inc. stock cheap compared to fundamentalsQuarterly Risk Review & Verified Swing Trading Watchlist - mfd.ru
Is aTyr Pharma Inc. backed by strong institutional buyingWeekly Trend Report & Smart Investment Allocation Tips - mfd.ru
Why hedge funds are buying aTyr Pharma Inc. stock2025 EndofYear Setup & Risk Managed Investment Entry Signals - mfd.ru
Why analysts upgrade aTyr Pharma Inc. stockJuly 2025 Fed Impact & Capital Protection Trade Alerts - mfd.ru
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: High-Growth - openPR.com
Is aTyr Pharma Inc. stock resilient to inflationJuly 2025 Market Mood & High Accuracy Trade Alerts - mfd.ru
Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected - RTTNews
Aug Summary: Does aTyr Pharma Inc have pricing powerJuly 2025 Reactions & Community Consensus Trade Signals - baoquankhu1.vn
Market Outlook: Does aTyr Pharma Inc have pricing powerJuly 2025 Pullbacks & High Conviction Investment Ideas - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: aTyr Pharma (ATYR), Pfizer (PFE) and Bicycle Therapeutics (BCYC) - The Globe and Mail
Atyr Pharma CFO Broadfoot sells $1.5k in stock - Investing.com
Atyr Pharma CEO Shukla sells $3.6k in stock By Investing.com - Investing.com Nigeria
Atyr Pharma CEO Shukla sells $3.6k in stock - Investing.com UK
Atyr Pharma CFO Broadfoot sells $1.5k in stock By Investing.com - Investing.com South Africa
aTyr Pharma general counsel sells $1091 in stock By Investing.com - Investing.com UK
aTyr Pharma general counsel sells $1091 in stock - Investing.com
FDA to review aTyr Pharma’s efzofitimod data in mid-April meeting - Investing.com Nigeria
aTyr Pharma gets FDA meeting on lead drug (ATYR:NASDAQ) - Seeking Alpha
Atyr Pharma announces scheduling of FDA type C meeting to discuss efzofitimod program in pulmonary sarcoidosis - marketscreener.com
aTyr Pharma (ATYR) Prepares for Key FDA Meeting on Efzofitimod - GuruFocus
aTyr Pharma Schedules FDA Meeting to Discuss Phase 3 EFZO-FIT™ Study Results for Efzofitimod in Pulmonary Sarcoidosis - Quiver Quantitative
ATyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis - marketscreener.com
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis - GlobeNewswire
3.69%
0.68%
자본화:
|
볼륨(24시간):